Skip to main content
SpringerLink
Log in

Clinical Research of Treatment with Tirofiban for High-Risk Non-ST-Segment Elevation Acute Coronary Syndrome During Peri-Operative Intervention Operation Period

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

The objectives of this study are to explore the clinical effects of treatment with tirofiban for high-risk non-ST-segment elevation acute coronary syndrome (NSTE ACS) during peri-operative intervention operation period and to improve the level of clinical treatment. Ninety cases of high-risk NSTE ACS patients were randomly selected from January 2011 to April 2013 as the research objects, which were divided into two groups: the control group and the observation group. The control group received conventional aspirin, clopidogrel anticoagulation, coronary angiography, and percutaneous coronary interventional (PCI) treatment, while the observation group took tirofiban treatment in addition to the treatment of control group. The differences in major adverse cardiovascular events, TIMI flow grading, and complications of the two groups were observed after treatment. There were significant differences (P < 0.05) in the distal vascular blockage of major adverse cardiovascular events, intra-operative no-reflow, reoccurrence of acute myocardial infarction and stenocardia, and post-PCI TIMI flow grades 2 and 3. But in terms of bleeding complications, and TIMI flow grades 0 and 1 before PCI and after PCI, there was no significant difference (P > 0.05). Application of tirofiban treatment for high-risk NSTE ACS during the peri-intervention period is safe and effective, which can improve TIMI flow, increase tissue perfusion, and reduce postoperative complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bolognese, L., Falsini, G., Liistro, F., et al. (2006). Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: The everest tr[J]. Journal of the American College of Cardiology, 47(3), 522–528.

    Article  CAS  PubMed  Google Scholar 

  2. Ohman, E. M., Van de Werf, F., Antman, E. M., et al. (2005). Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: Results of a randomized trial.[J]. The American Heart Journal, 150(1), 79–88.

    Article  CAS  Google Scholar 

  3. Steen, H., Lehrke, S., & Wiegand, U. K. (2005). Very early cardiac magnetic resonance imaging for quantification of myocardial tissue perfusion in patients receiving tirofiban before percutaneous coronary intervention for ST-elevation myocardial infarction [J]. American Heart Journal, 149(03), 564.

    Article  PubMed  Google Scholar 

  4. Seitz, R. J., Oberstrass, H., Ringelstein, A., et al. (2011). Failed recovery from thrombolysis is predicted by the initial diffusion weighted imaging lesion.[J]. Cerebrovascular Diseases, 31(6), 580–587.

    Article  PubMed  Google Scholar 

  5. Liu, T., Xie, Y., Zhou, Y. J., et al. (2009). Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions [J]. Chinese Medical Journal (English), 122(15), 1732–1737.

    Google Scholar 

  6. Valgimigli, M. (2010). Balancing safety and efficacy: Recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndrome [J]. European Heart Journal Supplements, 12(Suppl.D), D14–D23.

    Article  CAS  Google Scholar 

  7. Li, J.-P., Liu, Q., Huo, Y., et al. (2013). Rationale and design of the ETN-STEP (Early administration of tirofiban in mid to high risk patients with non-ST elevation acute coronary syndrome referred for percutaneous coronary intervention) project: A multi-center, randomized, controlled clinic trial in Chinese patients [J]. Journal of Geriatric Cardiology, 9(4), 375.

    Article  Google Scholar 

  8. Schwenkglenks, M., Brazier, J. E., Szucs, T. D., et al. (2011). Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes [J]. Value in Health, 14(1), 24–33.

    Article  PubMed  Google Scholar 

  9. Harrington, R. A., Becker, R. C., Cannon, C. P., et al. (2008). Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American college of chest physicians evidence-based clinical practice guidelines (8th edition).[J]. Chest, 133(6 SUPPL), 670S–707S.

    Article  CAS  PubMed  Google Scholar 

  10. Harrington, R. A., Becker, R. C., Cannon, C. P., et al. (2008). Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American college of chest physicians evidence-based clinical practice guidelines (8th edition).[J]. Chest, 133(6 SUPPL), 670S–707S.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Specific Diagnosis, General Hospital of Shenyang Military Area Command, 83 Wenhua Road, Shenhe District, Shenyang, 110016, China

    Nannan Liu, Mingxiao Hou, Junying Cao, Hongli Wu & Weiwei Zhou

  2. Department of Ultrasonography, Affiliated Shengjing Hospital, China Medical University, Shenyang, 110004, China

    Nannan Liu, Mingxiao Hou, Weidong Ren, Junying Cao, Hongli Wu & Weiwei Zhou

Authors
  1. Nannan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mingxiao Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weidong Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junying Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hongli Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weiwei Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mingxiao Hou.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, N., Hou, M., Ren, W. et al. Clinical Research of Treatment with Tirofiban for High-Risk Non-ST-Segment Elevation Acute Coronary Syndrome During Peri-Operative Intervention Operation Period. Cell Biochem Biophys 71, 43–47 (2015). https://doi.org/10.1007/s12013-014-0160-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0160-9

Keywords

Search

Navigation